Focus: AbCellera is a therapeutic antibody discovery company leveraging advanced platform technology to identify and develop monoclonal antibodies across multiple disease areas. Founded in 2015 and headquartered in Vancouver, BC, the company operates at mid-cap biotech scale with 501–1000 employees.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Growing — net +9 jobs in 30d
23 jobs added vs 14 removed. Steady team buildout.
A high-potential platform biotech with validating partnerships but unproven late-stage execution; suited for scientists betting on discovery-to-development leverage rather than near-term commercial upside.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AbCellera
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AbCellera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories - Investing.com
AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories Investing.com
AbCellera Biologics Stock Jumps 15% to New 52-Week High on Hot Flash Drug Momentum and Price Target Hike - International Business Times Australia
AbCellera Biologics Stock Jumps 15% to New 52-Week High on Hot Flash Drug Momentum and Price Target Hike International Business Times Australia
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity - finance.yahoo.com
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity finance.yahoo.com
AbCellera's nonhormonal menopause drug shows early success - Drug Discovery News
AbCellera's nonhormonal menopause drug shows early success Drug Discovery News
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - finance.yahoo.com
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? finance.yahoo.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing Pharmaceutical Executive
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo